S&P 5007,713▲ 0.28%Nasdaq26,425▼ 0.02%Dow Jones52,496▲ 1.02%Nasdaq 10029,490▼ 0.13%VIX17.31▼ 6.13%US Dollar101.73▼ 0.25%Gold spot4,145▲ 0.30%WTI spot101.91▲ 1.04%
KOSDAQ · Korea · Updated after 20 Oct 2026 close

EuBiologics Co. Ltd.

206650 · KOSDAQ · prices in KRW
KRW 7,870.00▼ -200.00 (2.48%)
Research reportHistorical data

About EuBiologics Co. Ltd.

EuBiologics is a South Korean biopharmaceutical company that develops and manufactures vaccines. Its main product is an oral cholera vaccine, which is supplied to public health programmes and international procurement agencies for use in outbreak response and prevention. The company also works on other vaccine candidates and contract manufacturing for partners. It is based in South Korea, where it carries out research, development and production of its vaccine products for customers and health organisations around the world.

EuBiologics Co. Ltd. trades under the code 206650 on the KOSDAQ in Korea, with its price quoted in South Korean won (KRW). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

49/ 100
Market X-Ray · price-based
Weak price profile
Ranks #987 of 1831 on the KOSDAQ · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Korea yet.
TrendWeak
36/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-27.4%
From 52-week high-51.4%
MomentumWeak
33/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-3.7%
6-month return-39.9%
12-month, skipping last month-36.4%
Stability (higher is calmer)Fair
66/100
Typical risk for this exchange.
See the numbers →
Volatility, 1 year (lower is calmer)47.7%
Worst drawdown, 1 year (smaller is calmer)-54.4%
LiquidityFair
70/100
Moderate trading activity.
See the numbers →
Avg daily value traded1,047.76M KRW
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Korea when fundamentals data for this market is added. All Korea stocks.
Price trend
Below its 200-day average
Versus its 50- and 200-day averages
52-week range
6,950.00 – 17,700.00
Price is 9% of the way up
Returns
−3.7% 3m · −40.4% 1y
Price returns, dividends not included
RSI (14)
39
Neutral zone

Price chart

52-wk range 6,950.00 – 17,700.00 Daily closes, split-adjusted

Signals

50-day average8,595.20
200-day average10,833.75
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)355.53

Technical summary

Daily
Strongly bearish
3 bullish · 1 neutral · 12 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 108,148.0Bearish
EMA 108,103.8Bearish
SMA 208,258.0Bearish
EMA 208,240.8Bearish
SMA 508,595.2Bearish
EMA 508,500.3Bearish
SMA 1008,714.1Bearish
EMA 1009,127.1Bearish
SMA 20010,833.8Bearish
EMA 20010,183.1Bearish
Oscillators (daily)
RSI (14)39.04Neutral
MACD (12, 26)-161.6Bearish
Momentum (12)-5.07Bearish
Stochastic %K (14)15.00Bullish
Williams %R (14)-85.00Bullish
CCI (20)-130.0Bullish
Pivot points (classic, last session)
S3
7,373.3
S2
7,596.7
S1
7,733.3
Pivot
7,956.7
R1
8,093.3
R2
8,316.7
R3
8,453.3
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in KRW. Educational only, not financial advice.